Get the Stockscreener App
7.12
0.71%
0.05
Pre-market:
7.11
-0.010
-0.14%
Satellos Bioscience Inc stock is traded at $7.12, with a volume of 49,904.
It is up +0.71% in the last 24 hours and down -38.78% over the past month.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$7.07
Open:
$6.92
24h Volume:
49,904
Relative Volume:
1.00
Market Cap:
$146.86M
Revenue:
-
Net Income/Loss:
$-21.94M
P/E Ratio:
-6.1195
EPS:
-1.1635
Net Cash Flow:
$-21.87M
1W Performance:
-1.11%
1M Performance:
-38.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.90
$7.44
1-Week Range:
$6.67
$8.37
52-Week Range:
$6.67
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
7.12 | 146.86M | 0 | -21.94M | -21.87M | -1.1635 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
MSLE Earnings History & Surprises | EPS & Revenue Results | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
MSLE News | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World
(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily
The Canadian biotech stock will beat the market, analyst says - Cantech Letter
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Satellos Bioscience Inc. - Mena FN
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget
Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks
Interim Duchenne and FSHD data on SAT-3247 from Satellos (NASDAQ: MSLE) - Stock Titan
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
(MSCL) Trading Performance and Risk Management (MSCL:CA) - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com
Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks
Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan
(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks
Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com
Inside Satellos’ experimental DMD pill at live online event - Stock Titan
(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily
US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks
(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat
Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):